Neonatal sepsis

Vaccinologists Keith Klugman and Shabir Madhi Awarded Sabin’s Prestigious Gold Medal; Infectious Diseases Epidemiologist Nicole Basta Receives Rising Star Award

Retrieved on: 
金曜日, 4月 19, 2024
Education, Science, Mentorship, MenAfriVac, Death, Vaccine, Life, Government, Rising Star Award, Klugman, Basta, Global health, Vaccination, Public, Diarrhea, Neonatal sepsis, Princeton University, Developing country, SAMRC, Meningococcal vaccine, Gold medal, DRS, Child, McGill University, RSV, Tomer Capone, Infection, National academy, Pneumonia, Pregnancy, Publication, Health, Research, Meningococcal disease, Sabin Vaccine Institute, Gold, Rotavirus, Student, Organization, GBS, University of the Witwatersrand, University, Canada Research Chair, Florida Department, CBE, Policy, Fever Dream, Disease, Meningitis, HPV, COVID-19

Fueled by an early interest in science as a child in South Africa -- in part due to a physician father – Klugman holds both a medical as well as a science doctorate degree from Wits University and was the first student in the school’s history to obtain them simultaneously. He began his research career nearly five decades ago investigating the typhoid vaccine and has since distinguished himself as a formidable infectious diseases’ scientist. Klugman is widely known for his work on pneumonia, which still kills a child under five every 43 seconds, many in the world’s poorest countries. As the director of the pneumonia program at the Seattle-based Bill and Melinda Gates Foundation, Klugman orchestrates strategic initiatives aimed at reducing deaths from pneumonia, RSV, neonatal sepsis, and meningitis. He has authored hundreds of publications that have been cited over 50,000 times to date and has been elected to the National Academy of Medicine in the United States. Klugman is also a professor emeritus of global health at Atlanta’s Emory University.

Key Points: 
  • Klugman first met his then-graduate student Madhi at South Africa’s University of the Witwatersrand (also known as Wits University), where Klugman established, and Madhi expanded, a now globally renowned infectious diseases research institute.
  • He began his research career nearly five decades ago investigating the typhoid vaccine and has since distinguished himself as a formidable infectious diseases’ scientist.
  • His scientific achievements aside, Klugman has long championed the need for the world’s poorest children to have equitable access to vaccines.
  • Sabin’s Rising Star award was created in 2020 to encourage and recognize the next generation of vaccine and immunization leaders.

SCOUT RECEIVES FUNDING FROM CARB-X TO DEVELOP A LOW-COST POINT-OF-CARE AND HOME DIAGNOSTIC FOR GONORRHEA AND CHLAMYDIA

Retrieved on: 
木曜日, 4月 18, 2024
Chlamydia trachomatis, FDA, Mortality, Administration, Pelvic inflammatory disease, Malaria, Death, Doctor of Philosophy, Vaccine, Development, Point-of-care testing, PHAC, Diagnosis, Gonorrhea, Novo Nordisk Foundation, Prevalence, HHS, Vertical loop, Neonatal sepsis, Infertility, OTC, Public Health Agency, Entrepreneurship, Infection, Urine, Neisseria gonorrhoeae, Patient, Ng, CARB-X, NIH, Education, BMBF, STI, Therapy, Disease, Bangladesh Technical Education Board, SARS-CoV-2, HIV/AIDS, Social work, NIAID, Bill, Physician

BOSTON, April 18, 2024 /PRNewswire/ -- Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) will award up to US$1 million to diagnostics and health tech company Scout to demonstrate proof-of-concept and feasibility ahead of development of a new point-of-care test – STI Scout. The test will detect and differentiate between Neisseria gonorrhoeae (Ng) and Chlamydia trachomatis (Ct). STI Scout is quick and inexpensive, with a turnaround time of 30 minutes and costs anticipated to be less than half of other options.

Key Points: 
  • STI Scout is quick and inexpensive, with a turnaround time of 30 minutes and costs anticipated to be less than half of other options.
  • Additionally, STI Scout can use either first void urine or vaginal swabs, and future tests will be able to guide therapy for gonorrhea treatment based on antibiotic susceptibility.
  • STI Scout uses the Scout Hub to run and the Scout Connect mobile app, which provides instructions, tracks results, and eventually will allow patients to connect digitally to a healthcare provider.
  • Scout's diagnostic is the second diagnostic and ninth project to receive a CARB-X award as part of the 2022-2023 funding call .

Vivacelle Bio Integrates Sub-Saharan Africa Strategy into Series B Financing Round

Retrieved on: 
木曜日, 2月 22, 2024
Blood pressure, Blood, School, Sepsis, Woman, IIA, Bleeding, Doctor of Philosophy, Resuscitation, The, Shock, MD, Diarrhea, Temperature, Septic, University, Nitric oxide, Shock (mechanics), Senior advisor, Finger, Life, Urinary tract infection, Risk, Internal bleeding, Pelvic floor dysfunction, Malaria, Hypovolemia, Nanoparticle, Gangrene, Neonatal sepsis, JD, Patient, Septic shock, Clinical trial, UMKC, Child, Reperfusion injury, Hypotension, Partnership

Targeted $20M Series B Round to include Sub-Saharan Africa in product development.

Key Points: 
  • Targeted $20M Series B Round to include Sub-Saharan Africa in product development.
  • Vivacelle Bio is partnering with Propelevate to drive the Sub-Saharan Africa strategy, which is fully integrated into its Series B financing round.
  • Through partnership with Propelevate, Vivacelle Bio will engage global health funders and stakeholders during final stages of product development, and Propelevate will drive Vivacelle Bio's go-to-market strategy for African markets upon regulatory approval.
  • "We are excited to partner with Vivacelle Bio because of their commitment to Sub-Saharan Africa.

CMMB Opens Newborn Care Unit at Ikanga Sub-County Hospital in Kenya

Retrieved on: 
月曜日, 11月 28, 2022
Infant, Infection, CMMB (Catholic Medical Mission Board), Neonatal sepsis, Breathe Me, Mother, CMMB, Health, Mortality, Asphyxia, Vital signs, Travel, Death, Ikanga, Thermoregulation, Volunteering, Jaundice, Poverty, Hospital, Medicine, Pharmaceutical industry

NAIROBI, KENYA, Nov. 28, 2022 (GLOBE NEWSWIRE) -- Catholic Medical Mission Board (CMMB) , a faith-based global health organization, opened a newborn care unit on Nov. 24 at the Ikanga Sub-County Hospital in Kitui County.

Key Points: 
  • NAIROBI, KENYA, Nov. 28, 2022 (GLOBE NEWSWIRE) -- Catholic Medical Mission Board (CMMB) , a faith-based global health organization, opened a newborn care unit on Nov. 24 at the Ikanga Sub-County Hospital in Kitui County.
  • This newborn care unit will allow babies to get the care they need right awayand save lives.
  • This is the third newborn care center that CMMB has renovated and opened in Kitui County over the past two years.
  • In 2021, CMMB opened newborn care units at the Mutomo Mission Hospital and the Ikutha Level IV hospital.

Global C-Reactive Protein Testing Market Research Report 2022 with Competitive Profiles of Thermo Fisher Scientific, F Hoffmann-La Roche, Danaher, Quest Diagnostics, & Siemens Healthineers - ResearchAndMarkets.com

Retrieved on: 
月曜日, 10月 24, 2022
Health, Biotechnology, Atherosclerosis, Risk, Glucose, Growth, Infection, Asia-Pacific, Smoking, Organization, C-reactive protein, Tissue, Inflammation, WHO, World, Acquisition, Obesity, Blood, Artery, CVD, Weight gain, American Heart Association, World Health Organization, Eating, CRP, Abcam, Cardiovascular disease, Degenerative disease, Death, Neonatal sepsis, Chronic obstructive pulmonary disease, Stroke, Dietary supplement, COPD, HB

The "C-Reactive Protein Testing Global Market Report 2022" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "C-Reactive Protein Testing Global Market Report 2022" report has been added to ResearchAndMarkets.com's offering.
  • The regions covered in the c-reactive protein testing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
  • The increasing cases of cardiovascular diseases (CVD) are expected to propel the growth of the c-reactive protein testing market.
  • Major companies operating in the c-reactive protein testing market are focused on providing technologically advanced solutions to strengthen their market position.

New Study Supports Cytovale IntelliSep Test as Promising Tool to Aid in the Rapid Diagnosis of Sepsis in the Emergency Department

Retrieved on: 
火曜日, 6月 22, 2021
Health, Medical devices, Infectious diseases, Hospitals, General Health, Clinical trials, Biotechnology, Medical specialties, Medicine, Clinical medicine, Sepsis, Neonatal sepsis, Sepsis Alliance

Data from the study, Assessment of a cellular host response test as a sepsis diagnostic for those with suspected infection in the Emergency Department , showed that Cytovales test is a promising tool to aid in the rapid diagnosis and risk stratification for sepsis.

Key Points: 
  • Data from the study, Assessment of a cellular host response test as a sepsis diagnostic for those with suspected infection in the Emergency Department , showed that Cytovales test is a promising tool to aid in the rapid diagnosis and risk stratification for sepsis.
  • In this study of patients presenting to the emergency department with signs or suspicion of infection, the authors found the IntelliSep test to be a reliable diagnostic indicator for sepsis.
  • This latest study evaluating Cytovales IntelliSep test makes a case that it is a potentially valuable tool to aid in the rapid diagnosis of sepsis in the emergency department.
  • The study assessed the performance of the IntelliSep test for evaluating sepsis risk in 266 adult patients who presented at emergency departments in Baton Rouge, La.

Jazz to Present New Data at ASCO and EHA 2021 Meetings Showcasing Clinical Advances Across Hematology and Oncology Portfolio

Retrieved on: 
木曜日, 5月 20, 2021
Health sciences, Health, Medicine, Leukopenia, Breastfeeding, Complete blood count, Prescription drug, HIV and pregnancy, Neonatal sepsis

Your doctor will monitor your blood counts during treatment with VYXEOS.

Key Points: 
  • Your doctor will monitor your blood counts during treatment with VYXEOS.
  • You are encouraged to report negative side effects of prescription drugs to the FDA.
  • Do not breastfeed during treatment with ZEPZELCA and for 2 weeks after your final dose of ZEPZELCA.
  • Some people with low white blood cell counts may get fever, or an infection throughout the body (sepsis), that can cause death.

Jazz to Present New Data at ASCO and EHA 2021 Meetings Showcasing Clinical Advances Across Hematology and Oncology Portfolio

Retrieved on: 
木曜日, 5月 20, 2021
Health sciences, Health, Medicine, Leukopenia, Breastfeeding, Complete blood count, Prescription drug, HIV and pregnancy, Neonatal sepsis

Your doctor will monitor your blood counts during treatment with VYXEOS.

Key Points: 
  • Your doctor will monitor your blood counts during treatment with VYXEOS.
  • You are encouraged to report negative side effects of prescription drugs to the FDA.
  • Do not breastfeed during treatment with ZEPZELCA and for 2 weeks after your final dose of ZEPZELCA.
  • Some people with low white blood cell counts may get fever, or an infection throughout the body (sepsis), that can cause death.

T2 Biosystems CEO Shares Personal Heart Transplant and Sepsis Survival Story in Newly Released Book

Retrieved on: 
火曜日, 3月 30, 2021
Medicine, Cardiac surgery, Heart transplantation, Organ transplantation, Sepsis, Neonatal sepsis

According to a study in The Lancet , nearly 11 million people died from sepsis globally in 2017 alone, representing nearly 20 percent of all global deaths.

Key Points: 
  • According to a study in The Lancet , nearly 11 million people died from sepsis globally in 2017 alone, representing nearly 20 percent of all global deaths.
  • As a result of his BSI and sepsis, Sperzels treatment included numerous antibiotics as well as a hospital readmission to ultimately address the hospital-acquired infection.
  • I am so grateful to my heart donor, and to those who worked hard to save my life before and after my heart transplant, said Sperzel.
  • I believe more people need access to T2 Biosystems technology because it can be a game-changer in the treatment of patients at risk of sepsis.

Sri Lankan Study Expands Evidence Demonstrating the Benefits of Critical Congenital Heart Disease (CCHD) Screening Using Masimo SET® Pulse Oximetry

Retrieved on: 
月曜日, 3月 22, 2021
Biotechnology, Health, Consumer, Surgery, Other Science, Research, Medical devices, Children, General Health, Hospitals, Baby, Maternity, Science, Clinical trials, Cardiology, Medicine, Clinical medicine, Medical specialties, Neonatology, Cardiology, Medical monitoring, Pulse oximetry, Masimo, Newborn screening, Neonatal sepsis, Pulse, Newborn Foundation

Gunaratne CR, Hewage I, Fonseka A, Thennakoon S. Comparison of pulse oximetry screening versus routine clinical examination in detecting critical congenital heart disease in newborns.

Key Points: 
  • Gunaratne CR, Hewage I, Fonseka A, Thennakoon S. Comparison of pulse oximetry screening versus routine clinical examination in detecting critical congenital heart disease in newborns.
  • Published clinical studies on pulse oximetry and the benefits of Masimo SET can be found on our website at http://www.masimo.com .
  • Impact of pulse oximetry screening on the detection of duct dependent congenital heart disease: a Swedish prospective screening study in 39,821 newborns.
  • Beyond Critical Congenital Heart Disease: Newborn Screening Using Pulse Oximetry for Neonatal Sepsis and Respiratory Diseases in a Middle-Income Country.